Viridian Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $120.0M | $45.9M |
| FY2021 | $0 | $187.7M | $42.3M |
| FY2022 | $4.6M | $395.1M | $155.6M |
| FY2023 | $20.2M | $442.0M | $102.8M |
| FY2024 | $20.6M | $671.6M | $99.6M |
| FY2025 | — | $722.2M | $212.4M |